A dose-response study of oral atenolol administered once daily in patients with raised intra-ocular pressure.
Oral atenolol (25, 50 and 100mg) and placebo administered once daily were tested in a double-masked, randomized cross-over study. Ten patients (18 eyes) who had untreated intraocular pressure (IOP) greater than or equal to 22 mm Hg participated. A fall in IOP was observed 2 h after administration, with a mean maximum after 2-5 h. The decrease in IOP was dose-dependent and persisted 24 h during treatment with the higher doses. After 7-day treatment a significant decrease in IOP was still noted 24 h after intake of 50 and 100 mg. The mean maximum decrease in IOP was observed at the same time as on day 1, but the fall in IOP was slightly diminished. During the treatment period a reduction in pulse rate was seen with all the doses tested. A fall in systemic blood pressure was also observed with the higher doses. Two patients reported side effects that could be related to haemodynamic influence.
D000284:Administration, Oral; D000368:Aged; D001262:Atenolol / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects; D011897:Random Allocation
D011412:Propanolamines; D001262:Atenolol